Back to Authors

DeCarli, Charles S.

Mayo Clinic

University of California, Davis

Citations 3

Does cohort heterogeneity affect relationships between AD biomarkers and cognition?
Liu, Peiwei, Taggett, Jacinda , Snyder, Heather M. , DeCarli, Charles S., Vemuri, Prashanthi, Harvey, Danielle J., Koeppe, Robert A., Jagust, William J., Landau, Susan M., Group, the Alzheimer's Disease NeuroImaging Initiative and the US POINTER Study, Harrison, Theresa M. , DeCarli, Charles , Vemuri, Prashanthi , Harvey, Danielle , Jagust, William J. , Baker, Laura D. , Landau, Susan, Group, the US POINTER Study

Alzheimer's & Dementia | December 25, 2025 | Volume: 21 | Issue: S2 | Pages: No page available

10.1002/alz70856_100140 Get It

Abstract Background Extensive evidence links cognition, tau, and neurodegeneration in Alzheimer's disease (AD). However, in U.S. POINTER imaging (a community‐recruited clinical trial cohort selected for high cardiovascular risk, ethnoracial diversity, and increased risk of cognitive decline and dementia) tau PET is more closely linked to cognition than in ADNI. Here, we further explore how ADNI and POINTER differ with respect to relationships between cross‐sectional AD biomarkers, cortical thickness, and different cognitive domains. Method U.S. POINTER imaging (Baseline; N = 775; 68.9±5.2 years, 62.8% female) and ADNI ( N = 405; 69.9±5.4 years, 58% female) were matched by age, sex, clinical status, and APOE4 genotype (Table 1). We examined associations between baseline AD biomarkers (Amyloid‐beta (Aβ) PET in centiloids, harmonized tau PET measures of MK6240 in POINTER and FTP in ADNI), regional cortical thickness, and verbal memory (Delayed Story Recall), executive function (Trail‐Making B), and global cognition (Preclinical Alzheimer's Cognitive Composite scores) across each cohort, controlling for age, sex, and education. Result Aβ burden in ADNI was associated with worse executive function ( p < .001) and global cognition ( p < .001) but not memory, whereas in POINTER Aβ burden was not associated with any cognitive domain (Figure 1A). Among Aβ+ individuals, tau burden was associated with poorer performance across domains in ADNI, but only with poorer verbal memory in POINTER (Figures 1B&1C). Additionally, there were stronger positive associations between cortical thickness and executive function and global cognition compared to verbal memory, particularly in ADNI Aβ+ individuals even after adjusting for entorhinal tau ( p < .01; Figure 2). Conclusion Cognitive performance was linked to all biomarkers (Aβ, tau, cortical thickness) but these associations were consistently stronger in ADNI compared to POINTER, particularly in Aβ+ individuals. The stronger thickness‐cognition relationships in ADNI were not driven by tau, indicating that there is a tau‐independent role of thickness in explaining cognition. In ADNI, there were subtle differences between cognitive domains such that executive function was more closely linked than verbal memory to Aβ and cortical thickness, whereas verbal memory was linked to tau in both cohorts. Our study highlights that frequently‐reported AD biomarker associations may be attenuated in heterogeneous, community‐recruited cohorts.
Risk factors and clinical relevance of MRI vascular markers in the U.S. POINTER study: a cross‐cohort comparison with the Framingham Heart Study
Vemuri, Prashanthi, Snyder, Heather M. , Beiser, Alexa S, Satizabal, Claudia L, Landau, Susan M., DeCarli, Charles S., Group, the US POINTER Study, Maillard, Pauline , Vemuri, Prashanthi , Baker, Laura D. , Beiser, Alexa , Satizábal, Claudia L. , Romero, José R. , Seshadri, Sudha , Landau, Susan, DeCarli, Charles

Alzheimer's & Dementia | December 25, 2025 | Volume: 21 | Issue: S2 | Pages: No page available

10.1002/alz70856_100134 Get It

Abstract Background Our objective is to examine the generalizability of the relationships between four MRI markers of CVD: DTI‐derived free water (FW), fractional anisotropy (FA), perivascular space (PVS) and white matter hyperintensities (WMH) volume, with vascular risk factors (VRF) and cognition in the baseline POINTER Imaging and Framingham Heart Study (FHS) cohorts. Method We studied 907 U.S. POINTER and 797 FHS Offspring participants with available baseline demographic, clinical and imaging data (Table 1). Continuous FW, FA, WMH (log‐transformed) and PVS measurements were regressed against total cranial volume (TCV). Cognitive outcomes included a Global Cognitive Composite and executive function composite score for POINTER and FHS. For each MRI marker, we used linear and logistic regressions to assess the effect of age, sex, hypertension, diabetes and smoking status, adjusting for ethnicity. We then assessed, for each cognitive outcome, the individual effect of MRI markers using separate linear regressions adjusted for demographic and clinical factors, as well as TCV‐adjusted gray matter volume to control for atrophy. Result POINTER and FHS differed across most demographic and biomarker characteristics (Table 1). Despite these differences, there were similar associations between demographic and VRF and the 4 MRI vascular markers in POINTER and FHS (Figure 1): increased age was associated with worse outcomes for the 4 markers, hypertension was associated with increased FW, PVS and lower FA, diabetes was associated with increased FW only, smoking status did not impact any of the four markers. Only exception was that female had lower FW and increased WMH in POINTER and increased PVS in FHS. Associations between CVD measures and cognition were also similar across cohorts: reduced cognitive performance was significantly associated with both decreased FA and increased FW (Figure 2), but not with WMH nor PVS. Conclusion Our study explores four imaging markers representing diverse mechanisms by which CVD could impact brain structure and function in the POINTER and FHS studies. Despite differences in cohort characteristics, we found mostly consistent CVD relationships with demographic, VRF, and cognitive measures between cohorts which supports the generalizability of the relation of these markers with VRF and cognition identified in the POINTER cohort.
Evaluation of Alzheimer's disease biomarkers and cognition in non‐Hispanic Black and non‐Hispanic White participants in ADNI and US POINTER Imaging
Robinson, Talia L. , Papp, Kathryn V, Snyder, Heather M. , Vemuri, Prashanthi, DeCarli, Charles S., Amariglio, Rebecca E. , Landau, Susan M., Group, Alzheimer's Disease Neuroimaging Initiative US POINTER Study, Harrison, Theresa M. , Papp, Kathryn V. , Baker, Laura D. , Vemuri, Prashanthi , DeCarli, Charles , Landau, Susan, Group, Alzheimer's Disease Neuroimaging Initiative US POINTER Study

Alzheimer's & Dementia | December 25, 2025 | Volume: 21 | Issue: S2 | Pages: No page available

10.1002/alz70856_100136 Get It

Abstract Background Given low representation of diverse populations in Alzheimer's disease (AD) research, it remains unclear if AD biomarker relationships observed primarily in non‐Hispanic White (NHW) cohorts generalize to other groups. Here we evaluate associations between key AD biomarkers and cognitive performance among cognitively unimpaired non‐Hispanic Blck (NHB) and NHW participants across 2 cohorts with unique sample characteristics. Method Participants included cognitively unimpaired NHB and NHW participants with Aβ and tau PET in ADNI (69 NHB, 402 NHW) and POINTER Imaging (135 NHB, 637 NHW). We examined harmonized measures of global Aβ (in centiloids), entorhinal cortex (EC) tau (quantified with MK6240 in POINTER and FTP in ADNI) and Preclinical Alzheimer's Cognitive Composite (PACC) scores. Regression models within each ethnoracial group evaluated relationships between 1) Aβ and EC tau, and 2) EC tau and PACC performance. Interaction models within each cohort were also conducted to assess differences in these associations by ethnoracial group. All models were adjusted for age and gender. Models with PACC additionally adjusted for education. Result In US POINTER, NHBs had lower Aβ and EC tau burden compared to NHWs (Table 1). In ADNI, there was no difference in EC tau between groups, and no differenence in Aβ after adjusting for age and gender. In US POINTER, the positive Aβ‐EC tau relationship was observed in both ethnoracial groups whereas in ADNI, Aβ was associated with higher EC tau in the NHW but not the NHB group. In both cohorts, EC tau was associated with worse PACC performance in both NHB and NHW and there were no differences in this association by ethnoracial group in interaction models (Figure 1). Conclusion NHBs had lower Aβ and EC tau than NHWs in POINTER but not ADNI, and there were inconsistent associations between Aβ and EC tau across cohorts. Despite these differences, AD biomarkers appear similarly related to cognitive outcomes across ethnoracial groups in both cohorts. Future analyses will attempt to further determine the generalizability of AD biomarker relationships in diverse samples by considering matching on relevant health and demographic characteristics, and inclusion of additional cohorts with harmonized biomarker and cognitive measurements.